Some of the most consequential AI in Australia this year isn’t writing marketing copy — it’s reading mammograms. South Australia has joined BRAIx, one of the country’s largest trials of artificial intelligence in cancer screening, a study designed to test whether an AI ‘reader’ working alongside radiologists can catch breast cancers earlier and ease a chronic shortage of specialists.
The trial, run through a research collaboration that includes the University of Adelaide and BreastScreen services in South Australia and Victoria, pairs an AI model with the human radiologists who currently double-read every screening mammogram. Backed by close to $3 million from the Federal Government’s Medical Research Future Fund, it is expected to involve in the order of 350,000 Australian women over an 18-month to two-year period.
What the AI actually does
Australia’s breast-screening program is built on a ‘two-reader’ model: every mammogram is examined independently by two radiologists, with a third brought in to resolve disagreements. It is thorough, but it is also labour-intensive at a time when radiologist availability is stretched. BRAIx tests whether an AI reader can stand in as one of those independent reads — flagging suspicious images for closer human attention and, potentially, fast-tracking the all-clear for the overwhelming majority of scans that are normal.
The prize is not just accuracy but speed. Women who screen today can wait around two weeks for a result; researchers hope an AI-assisted workflow can shorten that anxious window without compromising the safety net that double-reading provides.
Why South Australia matters here
Adding BreastScreen SA and the University of Adelaide gives the trial reach into a state that has been positioning itself as a hub for applied health AI. It also means the model is validated on South Australian women and imaging equipment, not just data from the eastern states — important, because AI screening tools can behave differently across populations and machines.
It lands alongside a broader push into clinical AI across the country, from hospital ‘scribe’ pilots to diagnostic decision support. What sets breast screening apart is the stakes and the scrutiny: this is a population program offered to healthy women, so the bar for evidence is deliberately high, and the AI is being tested as an assistant to clinicians rather than a replacement.
What’s next
The trial’s results will feed into decisions about whether — and how — AI reading is folded into BreastScreen Australia nationally. For now, the message from the researchers is cautious optimism: the technology is promising, but it earns its place in the clinic only if it can match the safety of the human-only system it is designed to support.
Sources: St Vincent’s Institute — BRAIx trial; FemTech World.
